Molecular Biosystems of San Diego announced last month that the European Medicines Evaluation Agency (EMEA) has accepted MBI's marketing authorization application (MAA) for FS069, a second-generation ultrasound contrast agent. If EMEA approves the
Molecular Biosystems of San Diego announced last month that the European Medicines Evaluation Agency (EMEA) has accepted MBI's marketing authorization application (MAA) for FS069, a second-generation ultrasound contrast agent. If EMEA approves the application, MBI and its marketing partner, Mallinckrodt of St. Louis, will be able to sell FS069 in all countries of the European Union.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.